Stay updated on Clinical Trial: INO-3112 & Durvalumab for HPV Cancers
Sign up to get notified when there's something new on the Clinical Trial: INO-3112 & Durvalumab for HPV Cancers page.

Latest updates to the Clinical Trial: INO-3112 & Durvalumab for HPV Cancers page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded: Revision: v3.4.2; the previous Notice about government funding and Revision: v3.4.1 were removed, indicating an administrative page revision update without changes to the study content.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a government funding status notice and updated the page revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedCosmetic text updates were made: a glossary display was added, QC-related labels were updated (e.g., 'Last Update Submitted that Met QC Criteria'), and the revision badge moved to v3.4.0, with minor casing adjustments to 'No FEAR Act Data'/'No FEAR Act data'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedRevision: v3.3.4 replaces v3.3.3. No substantive study content or functionality changes are indicated.SummaryDifference0.0%

- Check63 days agoChange DetectedAdded a dedicated Locations section and listed Texas as a location, replacing the previous Texas Locations grouping. Updated the revision to v3.3.3 and removed the HHS Vulnerability Disclosure link.SummaryDifference0.2%

- Check92 days agoChange DetectedThe page now displays Revision: v3.3.2, replacing Revision: v3.2.0.SummaryDifference0.0%

Stay in the know with updates to Clinical Trial: INO-3112 & Durvalumab for HPV Cancers
Enter your email address, and we'll notify you when there's something new on the Clinical Trial: INO-3112 & Durvalumab for HPV Cancers page.